Biochemical Engineering Special Interest Group
biological engineering professionals

Latest news

Singapore's Tessa raises $80M for T cell therapy push

Emerging immuno-oncology player Tessa Therapeutics has raised $80 million in a financing round that will be used to usher its virus-specific T cell (VST) immunotherapies through clinical trials. The company’s VST pipeline is currently headed by its TT10 VST therapy that targets tumors expressing Epstein-Barr virus proteins in a phase 3 trial for nasopharyngeal cancer, and a second candidate TT12 in phase 1 aimed at cervical and oropharyngeal cancers caused by human papillomavirus.

Latest news RSS feed

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).